Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03188991 · ClinicalTrials.gov registry record · Phase 2
Intracystic Injection of NanoPac® in Subjects With Mucinous Cystic Pancreatic Neoplasms
A Phase 2 study, sponsored by NanOlogy.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT03188991 is a Phase 2 study that has completed, run by NanOlogy. The registered enrollment target is 20 participants.
The verdict
NCT03188991, a Phase 2 study, has completed, sponsored by NanOlogy.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study will evaluate intracystic NanoPac® (Sterile Nanoparticulate Paclitaxel) administered via endoscopic ultrasound-guided fine needle injection (EUS-FNI) in subjects with mucinous cystic pancreatic neoplasms.
Interventions
- DRUG NanoPac®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-09-29 |
| Est. Completion | 2020-06-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03188991
The ClinicalTrials.gov registry entry for NCT03188991 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NanOlogy, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NanoPac® is the first listed.
NCT03188991 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03188991 about?
NCT03188991 is a clinical study titled "Intracystic Injection of NanoPac® in Subjects With Mucinous Cystic Pancreatic Neoplasms". This study will evaluate intracystic NanoPac® (Sterile Nanoparticulate Paclitaxel) administered via endoscopic ultrasound-guided fine needle injection (EUS-FNI) in subjects with mucinous cystic pancreatic neoplasms.
What is the current status of trial NCT03188991?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2017-09-29. Estimated completion is 2020-06-29.
What interventions are being tested in trial NCT03188991?
The interventions under investigation include: NanoPac® (DRUG).
Who is sponsoring clinical trial NCT03188991?
This trial is sponsored by NanOlogy, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.